JP2017532313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532313A5 JP2017532313A5 JP2017514888A JP2017514888A JP2017532313A5 JP 2017532313 A5 JP2017532313 A5 JP 2017532313A5 JP 2017514888 A JP2017514888 A JP 2017514888A JP 2017514888 A JP2017514888 A JP 2017514888A JP 2017532313 A5 JP2017532313 A5 JP 2017532313A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- amino acids
- acid residues
- sequence corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185138 | 2014-09-17 | ||
| EP14185138.6 | 2014-09-17 | ||
| PCT/EP2015/071359 WO2016042093A1 (en) | 2014-09-17 | 2015-09-17 | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532313A JP2017532313A (ja) | 2017-11-02 |
| JP2017532313A5 true JP2017532313A5 (https=) | 2018-10-04 |
| JP6783754B2 JP6783754B2 (ja) | 2020-11-11 |
Family
ID=51542245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514888A Active JP6783754B2 (ja) | 2014-09-17 | 2015-09-17 | 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11279771B2 (https=) |
| EP (1) | EP3194447B1 (https=) |
| JP (1) | JP6783754B2 (https=) |
| CN (1) | CN106687482B (https=) |
| ES (1) | ES2905085T3 (https=) |
| WO (1) | WO2016042093A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー／エス | 極性の組換え延長部を有するインスリン |
| CN108136043B (zh) | 2015-10-01 | 2022-09-06 | 诺和诺德股份有限公司 | 蛋白质缀合物 |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および／または消毒する方法 |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| JP2020501561A (ja) * | 2016-12-16 | 2020-01-23 | ザ・ユニバーシティ・オブ・シドニー | 脳卒中および関係する凝固性障害の処置のためのトロンビン阻害剤 |
| CN110505885A (zh) | 2017-04-05 | 2019-11-26 | 诺和诺德股份有限公司 | 寡聚体延伸的胰岛素-Fc缀合物 |
| CN117285632A (zh) * | 2022-06-17 | 2023-12-26 | 安源医药科技（上海）有限公司 | 针对tfpi的单克隆抗体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2334107A1 (fr) * | 1975-12-05 | 1977-07-01 | Pasteur Institut | Procede de couplage de substances biologiques par des liaisons covalentes |
| US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| AU2014200227A1 (en) | 2008-12-22 | 2014-01-30 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| WO2010072687A1 (en) * | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor (tfpi) |
| EP2379600B2 (en) * | 2008-12-22 | 2020-10-14 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| JP2013533871A (ja) * | 2010-06-30 | 2013-08-29 | ノヴォ ノルディスク アー／エス | 組織因子経路インヒビターに特異的に結合することが可能な抗体 |
| PE20141149A1 (es) * | 2011-04-01 | 2014-08-28 | Bayer Healthcare Llc | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) |
| WO2013141965A1 (en) * | 2012-03-21 | 2013-09-26 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| EP2827910A2 (en) | 2012-03-22 | 2015-01-28 | Baxter International Inc | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| CN104185474B (zh) | 2012-03-30 | 2017-08-25 | 拜尔健康护理有限责任公司 | 蛋白酶调节的抗体 |
| US10457743B2 (en) * | 2013-07-19 | 2019-10-29 | Novo Nordisk A/S | Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
-
2015
- 2015-09-17 CN CN201580050660.3A patent/CN106687482B/zh active Active
- 2015-09-17 JP JP2017514888A patent/JP6783754B2/ja active Active
- 2015-09-17 EP EP15763621.8A patent/EP3194447B1/en active Active
- 2015-09-17 US US15/508,229 patent/US11279771B2/en active Active
- 2015-09-17 WO PCT/EP2015/071359 patent/WO2016042093A1/en not_active Ceased
- 2015-09-17 ES ES15763621T patent/ES2905085T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532313A5 (https=) | ||
| JP2020500538A5 (https=) | ||
| CO2019006657A2 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| AR075798A1 (es) | Proteinas de union a il-17 (interleuquina 17) | |
| NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| JP2015508762A5 (https=) | ||
| HRP20171472T1 (hr) | Optimizirana monoklonska protutijela protiv inhibitora puta tkivnog faktora (tfpi) | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| JP2016512214A5 (https=) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| JP2017529097A5 (https=) | ||
| JP2017113028A5 (https=) | ||
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| JP2017528476A5 (https=) | ||
| JP2016529229A5 (https=) | ||
| HRP20250666T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
| JP2012509881A5 (https=) | ||
| JP2017522903A5 (https=) | ||
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| FI2691417T4 (fi) | Vasta-aineen Fc-variantteja |